about
Novel non-AR therapeutic targets in castrate resistant prostate cancerUse of a novel parenchymal clamp for laparoscopic and open partial nephrectomyCombined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study.Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records.Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?Periprostatic adipose tissue and prostate cancer progression: new insights into the tumor microenvironment.Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review).Diet, obesity, and cancer progression: are adipocytes the link?Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer.Active surveillance in patients with a PSA >10 ng/mL.The effect of nerve-sparing surgery on patient-reported continence post-radical prostatectomy.Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies.Comparison of epidural and intravenous patient controlled analgesia in patients undergoing radical cystectomy.Rational cotargeting of Pim-1 and Akt in prostate cancer.Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.Sex steroids in the tumor microenvironment and prostate cancer progression.Results of a national population-based study of outcomes of surgery for renal tumors associated with inferior vena cava thrombus.Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancerSmall incidentally discovered testicular masses in infertile men--is active surveillance the new standard of care?Is 24-hour urinary calcium a surrogate marker for dietary calcium intake?Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 TrialReceipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?Switching from a gonadotropin-releasing hormone (GnRH) agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysisAnalysis of the translatome in solid tumors using polyribosome profiling/RNA-SeqPlasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients
P50
Q28383663-CC3B61D9-D5FA-4FD5-950C-598AEBB83D4BQ34179315-92F318CC-E346-4014-A9B7-F9336D98FE54Q35980053-94F1AF9C-0866-4E6E-8B25-EF9930F8BD61Q37342938-42C787A8-3C89-4458-9FC7-890CD1D4D697Q37911769-4D466820-CA3A-4C32-9E8B-B73BB4A781E9Q38077183-C9101869-EA9E-4A94-92FC-19CD795B391DQ38165596-7BCB9300-849A-4EA9-AD77-A95B3CFDE788Q38239630-446BC36D-7F27-45A1-A5B9-57BBF69C2F94Q38256347-D010F3D7-9CD9-46BD-A33B-A1D03589C73DQ38963418-B5416931-E707-4FF2-B1B8-6CCA494EC025Q39984274-C88D2F2B-C369-45F4-BD0E-B3825BB9EF32Q41816172-0F9C53A9-9ADD-4DB5-B05C-4B8F898D96D7Q42134022-192E02C5-36C1-4073-81C1-955EB8C5F613Q42160072-2856FACC-770A-4F53-A226-A910EADA7B69Q43294016-8589E957-7F71-459C-B72F-E854C4183071Q43499043-11F20F8A-1959-4EF9-AC5B-2E23A777A277Q48252578-A83AD123-286D-4A40-B52A-1596745BE9A4Q50111698-48B3C5A1-B620-400F-9BC7-61488C1B65D2Q50778434-B44C4633-AD6C-4D38-9AE8-2F7C9471DB60Q57109073-03FF13AC-F9BA-4CC7-A69F-E16C723C9C93Q57645640-D3055606-27ED-45DB-98CB-81EC84834368Q81550812-E33D7A22-6A18-4737-A27C-67B6E1AAE1E5Q90321539-4596C525-E4E4-44B4-BB19-FA0C01073414Q90596570-9CE2E269-6875-49A8-A2CC-AA97F5D6BE91Q92203321-604005CA-A603-4D1E-BBD9-47283FD16563Q92893087-1D3FF6C6-DE70-4CD1-BE49-ACEDAB1DADEBQ93052675-63123B6E-CB7E-44A9-B86D-7D537EA25E70
P50
description
uro-oncologist and university professor
@en
uro-oncologue et professeur d'université
@fr
wetenschapper
@nl
հետազոտող
@hy
name
Paul Toren
@ast
Paul Toren
@en
Paul Toren
@es
Paul Toren
@fr
Paul Toren
@nl
type
label
Paul Toren
@ast
Paul Toren
@en
Paul Toren
@es
Paul Toren
@fr
Paul Toren
@nl
prefLabel
Paul Toren
@ast
Paul Toren
@en
Paul Toren
@es
Paul Toren
@fr
Paul Toren
@nl
P106
P69
P1153
34972293300
P21
P31
P496
0000-0002-5762-5787
P6634
paul-toren-99331083